Efficacy of dapagliflozin in treatment of coronary heart disease and heart failure with preserved ejection fraction patients

doi:10.3969/j.issn.1006-7795.2024.04.023

Abstract

Abstract: Objective To observe the improvement effect of dapagliflozin on cardiac function in patients with heart failure with preserved ejection fraction (HFpEF) complicated with coronary heart disease. Methods Patients with coronary heart disease and HFpEF who were hospitalized in the Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University from January 2021 to September 2022 were selected as the research objects. Among them, 69 patients who took dapagliflozin were selected as the dapagliflozin group, and 81 patients who did not take dapagliflozin were selected as the control group. Patients in both groups were treated with standard secondary prevention of coronary heart disease. If there were no contraindications, both groups were given standardized treatment for heart failure. The basic patients’ information were collected by the hospital information system, as well as outpatient follow-up data for 12 months of hospitalization and discharge, including blood glucose, blood lipids, N-terminal pro B-type natriuretic peptide (NT-proBNP) and other laboratory indicators, left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left ventricular end-systolic dimension (LVESD), left ventricular posterior wall thickness (LVPWT), stroke volume (SV), left ventricular diastolic function E/e'avg et al. And record the cardiac death, acute left heart failure, re-hospitalization for heart failure, re-hospitalization for angina, and adverse drug reactions during hospitalization. Results The degree of blood lipid and blood glucose control and the improvement of NT-proBNP, LVEF and E/e 'avg in the dapagliflozin group were better than those in control group, the differences were statistically significant (P<0.05). During the follow-up period, the incidence of acute left heart failure and rehospitalization due to heart failure in the dapagliflozin group was significantly lower than those in control group, the differences were statistically significant (P<0.05). Conclusions Dapagliflozin can improve cardiac diastolic function, reduce NT-proBNP levels, improve quality of life, and readmission rate for heart failure in patients with coronary heart disease complicated with HFpEF. Simultaneously, it has good security.

Key words: dapagliflozin, coronary heart disease, heart failure with preserved ejection fraction

CLC Number:

R541

Hou Dongyan, Feng Dan, Li Na. Efficacy of dapagliflozin in treatment of coronary heart disease and heart failure with preserved ejection fraction patients[J]. Journal of Capital Medical University, 2024, 45(4): 715-720.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2024.04.023

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2024/V45/I4/715

References

［1］ Anderson T, Hummel S L, Konerman M C. Epidemiology, diagnosis, pathophysiology, and initial approach to heart failure with preserved ejection fraction［J］. Cardiol Clin, 2022, 40(4): 397-413.
［2］ Solomon S D, McMurray J J V, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction［J］. N Engl J Med, 2022, 387(12): 1089-1098.
［3］ Montero-Pérez-Barquero M, Escobar-Cervantes C, Arévalo-Lorido J C, et al. Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice［J］. Future Cardiol, 2023, 19(6): 343-351.
［4］ Adamson C, Kondo T, Jhund P S, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial［J］. Eur Heart J, 2022, 43(41): 4406-4417.
［5］葛均波，徐永健，王辰．内科学［M］．北京：人民卫生出版社，2018： 168.
［6］射血分数保留的心力衰竭诊断与治疗中国专家共识制定工作组. 射血分数保留的心力衰竭诊断与治疗中国专家共识2023［J］. 中国循环杂志, 2023, 38(4): 375-393.
［7］ Committee Members, Cheitlin M D, Armstrong W F, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/ASE Committee to update the 1997 guidelines for the clinical application of echocardiography)［J］. Circulation, 2003, 108(9): 1146-1162.
［8］ Heidenreich P A, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines［J］. Circulation, 2022, 145(18): e876-e894.
［9］廖玉华, 杨杰孚, 张健, 等. 舒张性心力衰竭诊断和治疗专家共识［J］. 临床心血管病杂志, 2020, 36(1): 1-10.
［10］ Pandey A, Shah S J, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review［J］. J Am Coll Cardiol, 2021, 78(11): 1166-1187.
［11］ Pagel P S, Tawil J N, Boettcher B T, et al. Heart failure with preserved ejection fraction: a comprehensive review and update of diagnosis, pathophysiology, treatment, and perioperative implications［J］. J Cardiothorac Vasc Anesth, 2021, 35(6): 1839-1859.
［12］ Komiyama M, Agewall S, Hasegawa K. Future of antithrombotic therapy for heart failure with coronary artery disease［J］. Eur Heart J Cardiovasc Pharmacother, 2022, 8(5): e25.
［13］ Pabon M, Claggett B L, Wang X W, et al. Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial［J］. Eur J Heart Fail, 2023, 25(9): 1663-1670.
［14］ Anker S D, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction［J］. N Engl J Med, 2021, 385(16): 1451-1461.
［15］ Butt J H, Adamson C, Docherty K F, et al. Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial［J］. Circ Heart Fail, 2021, 14(12): e008837.
［16］ Jhund P S, Kondo T, Butt J H, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER［J］. Nat Med, 2022, 28(9): 1956-1964.
［17］ Vaduganathan M, Docherty K F, Claggett B L, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials［J］. Lancet, 2022, 400(10354): 757-767.
［18］ Teerlink J R, Diaz R, Felker G M, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure［J］. N Engl J Med, 2021, 384(2): 105-116.

[1]	Li Lina, Yang Minfu. Current status and prospect of cardiovascular fibroblast imaging [J]. Journal of Capital Medical University, 2024, 45(1): 46-51.
[2]	Luo Xiaomeng, Jiang Xue, Du Fenghe, Guo Caixia. Levels of sRAGE and IFN-γ in the plasma of patients with acute coronary syndrome and their relationship with the severity of coronary artery lesions [J]. Journal of Capital Medical University, 2023, 44(2): 272-279.
[3]	Wang Rongrong, Tian Junping. Correlation between serum calcium and cardiovascular outcome in patients with acute coronary syndrome [J]. Journal of Capital Medical University, 2023, 44(1): 154-160.
[4]	Feng Li, Yang Jiaxue, Li Xin, Jia Changqi, Jiang Chenxi. Functional change of hERG1a mutation H70R on hERG1a homomeric current and hERG1a/1b heteromeric currents [J]. Journal of Capital Medical University, 2022, 43(5): 747-753.
[5]	Ma Yixin, Zhang Zhongying, Si Sicong, Luo Hongyu, Zhao Huan, Yang Wei. The relationship between the new adipokines visfatin and vaspin expression in patients with type 2 diabetes mellitus and left ventricular hypertrophy [J]. Journal of Capital Medical University, 2022, 43(5): 767-773.
[6]	Chen Lu, Guo Xinying, Liu Jian, Du Fenghe, Guo Caixia. Correlation analysis of soluble advanced glycation end product receptors and renal function in patients with coronary atherosclerotic heart disease [J]. Journal of Capital Medical University, 2022, 43(2): 167-172.
[7]	Su Wen, Li Hongwei, Chen Hui, Li Weiping. Effect of D-dimer on long-term prognosis in patients with acute myocardial infarction [J]. Journal of Capital Medical University, 2022, 43(2): 173-177.
[8]	Wang Qian, Zhang Jiakun, Liu Qing, Sun Lin, Li Jingjie. M2 macrophage promotes myocardial regeneration by modulating nerve regeneration and angiogenesis in neonatal mice [J]. Journal of Capital Medical University, 2022, 43(2): 178-186.
[9]	Miao Zupei, Zhang Yinghua, Xiao Keling, Si Jin, Zhang Haoyu, Li Jing. Influence of obesity on the prognosis of patients with STEMI [J]. Journal of Capital Medical University, 2022, 43(2): 192-198.
[10]	Xia Ning, Nie Xiuhong, Wang Hao, Fan Xiaojun. Association of OSA and asthma with the incidence rate of coronary heart disease [J]. Journal of Capital Medical University, 2022, 43(1): 138-142.
[11]	Su Yunjuan, Wang Jingjing, Han Xiaotao, Liu Haiyan, Chen Yongfu, Yang Liu, Wu Qiming. Risk factors and predictive value of Framingham Risk Score of young men with coronary artery disease [J]. Journal of Capital Medical University, 2022, 43(1): 143-148.
[12]	Fang Ye, Zou Lin, Li Xiao, Lin Jing, He Wei. Correlation of Rock1 level with endothelial function and carotid intima-media thickness in elderly patients with unstable angina pectoris [J]. Journal of Capital Medical University, 2021, 42(6): 1081-1085.
[13]	Hu Bin, Zhou Yujie, Jia Dean, Qin Zheng, Xu Xiaohan, Yang Shiwei, Zhou Zhimin. Observation on effect of rotational atherectomy followed by drug-eluting stents implantation in patients age ≥65 years with severe calcified coronary lesions [J]. Journal of Capital Medical University, 2021, 42(1): 101-104.
[14]	Li Xiang, Pu Lianmei, Ruan Yang, Li Hong, Jin Zening. The relationship between ADIPOR1 rs7539542 and the susceptibility of coronary artery disease and type 2 diabetes in Han population [J]. Journal of Capital Medical University, 2020, 41(6): 935-942.
[15]	Li Xing, Lu Zijin, Wang Xiaodong, Wang Wei. Anti-platelet strategies in patients with percutaneous coronary intervention based on CYP2C19 gene polymorphism and platelet function [J]. Journal of Capital Medical University, 2020, 41(6): 960-964.